ArticleBiochemical pharmacology2018

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.

Yongwei Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.